Solid-state carbon NMR characterization of the polymorphs of roxifiban

Journal of Pharmaceutical and Biomedical Analysis

Volumn 30, Issue 1, 2002, Pages 125-129

  Vickery, Rodney D ^a   Nemeth, Gregory A ^a   Maurin, Michael B ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b QS Pharma   (United States)

Author keywords

13C CP MAS NMR; Polymorph; Roxifiban; Solid state nuclear magnetic resonance

Indexed keywords

ROXIFIBAN; AMIDINE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; FIBRINOGEN RECEPTOR; ISOXAZOLE DERIVATIVE;

ARTICLE; CALIBRATION; CARBON NUCLEAR MAGNETIC RESONANCE; CRYSTAL STRUCTURE; DRUG PURIFICATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SPECTRUM; STATISTICAL PARAMETERS; CRYSTALLIZATION; DRUG ANTAGONISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

AMIDINES; CALIBRATION; CRYSTALLIZATION; INDICATORS AND REAGENTS; ISOXAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0037158503     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(02)00203-0     Document Type: Article

References (8)

1. Polymorphism of Roxifiban
2. Polymorph determination for the GP IIb/IIIa antagonist, roxifiban, using a combination of electron diffraction and synchrotron X-ray powder diffraction techniques